Enzymatic method for the determination of Perindopril erbumine and Repaglinide in bulk and dosage forms

A. PRAMEELA RANI 1*, C. BALA SEKARAN² and Ch. SRILAKSHMI³

¹Department of Pharmaceutics, K.V.S.R. Siddhartha College of Pharmaceutical Sciences, Vijayawada - 520 010 (India).

²Department of Biotechnology, Jagarlamudi Kuppuswamy Chowdary College, Guntur - 522 006 (India). ³Department of Biochemistry, P.B.Siddhartha College of Arts & Science, Vijayawada - 520 010 (India).

(Received: February 28, 2009; Accepted: March 24, 2009)

ABSTRACT

Two simple and sensitive enzymatic methods were developed for the determination of Perindopril erbumine (method A) and Repaglinide (method B) either in raw material or in pharmaceutical formulations. Both methods A and B are based on oxidative coupling reaction between drug and 3-methylbenzothiazolin-2-one hydrazone (MBTH) in the presence of Hydrogen peroxide and enzyme horseradish peroxidase to produce colored product, which is measured spectrophotometrically at 425nm and 440nm respectively. Beer's law is obeyed in the concentration range of 10-50 µg/ml and 8-40 µg/ml for method A and method B respectively. The proposed methods were successfully applied to the assay of perindopril erbumine and repaglinide in tablet preparations with recoveries varying from 99.50 to 100.50% and 99.75 to 100.15%, with standard deviation of 0.0015 for method A and 0.00118 for method B. The results were statistically compared with those of the reference method. No significant interference was observed from the excipients commonly used as pharmaceutical aids with the assay procedure.

Key words: Perindopril erbumine, Repaglinide, Sandell's sensitivity, Beer's Law.

INTRODUCTION

Perindopril erbumine¹, (2S,3(infinity)S,7(infinity)S) - 1 - [(S) - N - [(S) - 1 - C a r b o x y - butyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1ethyl ester, compound with tert-butylamine (1:1), belongs to a group called angiotensin converting enzyme (ACE) inhibitors. The effect of this drug is, it drops down the blood pressure and decreases the workload of the heart. Literature survey revealed that few analytical methods have been reported for the estimation of Perindopril erbumine; spectrophotometric²⁻⁴, HPLC^{5,6}, LC–MS/MS^{7,8}.

Repaglinide, chemically, (S)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl) phenyl] butyl] amino]-2-oxoethyl] benzoic acid, is a new nonsulphonyl urea oral hypoglycemic drug⁹. It is used in the treatment of type-2 diabetes mellitus¹⁰. A few analytical methods have been reported for its quantitative estimation in pharmaceutical formulations, which include visible spectrophotometric^{11,12}, HPLC¹³ and electrochemical¹⁴ methods.

To the best of our knowledge, there is no work in the literature reported about the enzymatic method for the analysis of perindopril erbumine and repaglinide in either biological fluids or pharmaceutical formulations. Hence the author has made an attempt to develop two simple, sensitive and rapid spectrophotometric methods for the estimation of perindopril erbumine and repaglinide in bulk drugs and in pharmaceutical formulations.

EXPERIMENTAL

Apparatus

An ELICO Model SL-159 double beam, UV-VIS spectrophotometer (Elico India Ltd.,India) with 1.0 cm matched quartz cells was used for absorbance measurements. Systronics digital pH meter was used to adjust and determine the hydrogen ion concentration (pH) of the solutions.

- Remi desktop centrifuge with 24,000 rpm for the extraction of horseradish peroxidase (HRP).
- Homogenizer with a high speed blender 3-4
 × 15 sec. for homogenization of Horseradish root.

Materials and Reagents

All materials and reagents were of analytical grade and double distilled water was used.

- Perindopril erbumine and Repaglinide bulk samples (gift sample from local Pharmaceutical industry)
- Aqueous solutions (0.2%) of MBTH.
- Yeldstring Hydrogen peroxide (0.01M): Prepared by dissolving 0.10 ml of $30\% H_20_2$ in 200ml of reagent grade distilled water just prior to experiments.
- Phosphate buffer (0.1M, pH-7.0): Potassium dihydrogen phosphate-di sodium hydrogen phosphate buffer was prepared as follows.

Stock Solutions for buffer

- 0.5 M KH₂PO₄ solution: 68.04g of KH₂PO₄ is dissolved in 1 liter of reagent grade distilled water.
- O.5 M Na₂HPO₄ solution: 71g of Na₂HPO₄ is dissolved in 1 liter of reagent grade distilled water.

39 ml of 0.5 M KH_2PO_4 + 53.6 ml of 0.5 M NaH₂PO₄ were diluted to 1000 ml at 25°C.

Standard and Sample solution of Perindopril erbumine and Repaginide:

Method A

Accurately weighed 100mg of Perindopril erbumine was dissolved in 100ml of distilled water to give a concentration of 1mg/ml. The final concentration was brought to 200 µg/ml.

Method B

Accurately weighed 100mg of repaglinide was dissolved in 100ml of methanol to give a concentration of 1mg/ml. The final concentration was brought to 400 μ g/ml.

Extraction of the enzyme (Horseradish Peroxidase)

A turnip (Horseradish root) weighing 40 g was Peeled, washed, and cut into 1" cubes. The sliced pieces were homogenized in 200 mL of buffer in a blender at high speed for 15 minutes. The extract is clarified by centrifugation (10-15,000 rpm/ 10 min.) and filtered through Whatman No. 1 filter paper. The extract for stability was stored in toluene for at least a week at 4°C. The extract was suitably diluted for further experimental analysis

Assay Procedure Method A

Into a series of 25ml calibrated test tubes, 15ml buffer (pH 7.0) solution, 2 ml of reagent (MBTH), 1 ml of hydrogen peroxide (0.01M) and 1 ml horse radish root solution (1:1diluted) and aliquots of perindopril erbumine solution, were added and made up to the mark with distilled water. The tubes were incubated at room temperature for 15 minutes. The absorbance was measured after complete color formation at I_{max} of 425 nm against reagent blank. The amount of the drug in the sample was computed from corresponding calibration graph.

Method B

Into a series of 25ml calibrated test tubes, 15ml buffer (pH 7.0) solution, 2 ml of reagent (MBTH), 1 ml of hydrogen peroxide (0.01M) and 1 ml horse radish root solution (1:1diluted) and aliquots of repaglinide solution, were added and made up to the mark with distilled water. The tubes were incubated at room temperature for 15 minutes. The absorbance was measured after complete color formation at λ_{max} of 440 nm against reagent blank. The amount of the drug in a given sample was computed from the corresponding calibration graph.

RESULTS AND DISCUSSION

The methods A and B are based on the oxidative coupling reaction of the drugs, perindopril erbumine and repaglinide, with 3-methylbenzothiazolin-2-one hydrazone (MBTH) in the presence of hydrogen peroxide and horseradish peroxidase enzyme to give a colored product. Actually, this is an enzyme catalyzed oxidative coupling reaction of MBTH with the drugs. Under

92

the reaction conditions, on oxidation by the enzyme in the presence of hydrogen peroxide, MBTH loses two electrons and one proton forming an electrophilic intermediate, which is the active coupling species. This intermediate undergoes electrophilic substitution with perindopril erbumine and repaglinide to form the colored product which shows λ_{max} at 425nm and 440nm respectively. The colored products were found to be stable for 5 hours (method A) and 4 hours (method B) at room temperature.

Investigation of Assay Parameters Order of addition of reactants

The suitable order or addition of reactants in the determination of perindopril erbumine (method A) and repaglinide (method B) for attaining maximum color and stability was buffer-MBTHhydrogen peroxide-peroxidase enzyme-drug.

Effect of variation of temperature

All experiments and absorbance measurements were carried out at laboratory temperature ($28^{\circ}\pm3^{\circ}$). At low temperatures ($20^{\circ}C$) the time required for attaining maximum color is more. At high temperatures ($35^{\circ}C$) the stability of the colored species is less. So laboratory temperature is preferred for both the mthods.

Effect of Reagent Concentration

2 ml of 0.2% w/v MBTH and 1 ml of 0.01M hydrogen peroxide was the most suitable concentration for the proposed spectrophotometric methods.

Parameters	Method A(Perindopril)	Method B(Repaglinide)
λ _{max} (nm)	425	440
Beer's law limit (ìg/ ml)	10 - 50	8 – 40
Sandell's Sensitivity (ìg/cm²/0.001 abs. unit)	0.0806	0.0373
Molar absorptivity(Litre.mole ⁻¹ .cm ⁻¹)	2.547 × 10⁴	1.210 × 104
Stability of Color (hours)	5	4
Regression equation (Y)*		
Intercept (a)	0.009	-0.0106
Slope(b)	0.0011	0.0027
% RSD ^{\$}	1.2	0.555
% Range of errors (95% confidence limits):		
0.05 significance level	1.01	0.464
0.01 significance level	1.48	0.686
Correlation coefficient®	0.9998	0.9996

Table 1: Optical characteristics, precision and accuracy of proposed methods

* Y = a + bx, where Y is the absorbance and x is the concentration of drug in μ g/ ml \$ For six replicates

Formulations	Labelled amount(mg)	Recovery by reference method (%) [*]	Recovery by Proposed methods (%)**
Perindopril			
Tablet I	4	99.5	100.5
Tablet I	4	100.25	99.5
Repaglinide			
Tablet I	0.5	98.5	99.75
Tablet I	0.5	99.4	100.15

* Reference method was UV method developed in the laboratory.

** Recovery amount was the average of six determinants

Effect of pH

Different phosphate buffers with pH range of 5-8 were tried and pH 7 was the pH of choice for getting maximum absorbance.

Volume of buffer

15 ml of buffer was needed to bring the suitable pH in 25 ml of solution.

Optical Characteristics and Validation of the Methods:

Optical characteristics for both the methods, such as Beer's law limits, molar absorptivity and Sandell's sensitivity, are given in Table -1. The linearity, slope and the intercepts were calculated using the regression equation. Precision and accuracy of the proposed methods were tested by carrying out the determination of six replicates of pure and commercial samples of the drug, whose concentration was within Beer's law range. Values of relative standard deviation (RSD) and range of error at 95% confidence level were calculated for all the methods and are shown in Table 1.

Analysis of pharmaceutical preparations

Application of the proposed methods to the determination of perindopril erbumine and

repaglinide in its dosage forms was successfully made; the results are presented in Table-2. The excellent recoveries obtained indicated the absence of any interference from the excipients.

CONCLUSION

The proposed methods were found to be simple, economical, selective and sensitive. The statistical parameters and recovery study data clearly indicate the reproducibility and accuracy of the methods. Analysis of the authentic samples containing perindopril erbumine and repaglinide showed no interference from the common excipients. Hence, these methods could be considered for the determination of perindopril and repaglinide in the quality control laboratories.

ACKNOWLEDGEMENTS

The authors are grateful to Managements of Siddhartha Academy, Vijayawada, and Jagarlamudi Kuppuswamy Chowdary College, Guntur for their continuous support and encouragement and for providing the necessary facilities.

REFERENCES

- 1. Bounhoure J.P., Bottineau G., Lechat P, *et al. Clin Exp Hypertens.*, A **11**: 575-86 (1989).
- Abdellatef H. E., *J Pharm Biomed Anal*, **17**(8): 1267-70 (1998).
- Abdellatef H.E., Ayad M.M., Taha E.A., Journal of Pharmaceutical and Biomedical Analysis, 18(6): 1021-27 (1999).
- Erk N., Journal of Pharmaceutical and Biomedical Analysis, 26(1): 43-52 (2001).
- Abdalla A. Elshanawane, Samia M. Mostafa and Mohamed S. Elgawish, *Chromatographia*, 67: 837-40 (2008).
- Medenica M, Ivanovic D, Maskovic M, Jancic B, Malenovic A., *J Pharm Biomed Anal*, 44(5): 1087-94 (2007).
- Deepak S. Jain^{a. b}, Gunta Subbaiah^b, Mallika Sanyal^e, Umesh C. Pande^a and Pranav Shrivastav, *Journal of Chromatography B*, 837(1): 92-100 (2006).
- 8. Nirogi R.V., Kandikere V.N., Shukla M,

Mudigonda K, Maurya S, Komarneni P, *Rapid Commun Mass Spectrom*, **20**: 1864-70 (2006).

- 9. Budavari S., Eds., In; *The Merck Index,* 12th Edn., Merck & Co., Inc., Whitehouse Station, NJ, 8308 (1996).
- Reynolds J.E.F., Martindale, 33rd Edn., The Complete Drug Reference, Pharmaceutical Press, London, 334 (2002).
- 11. Singhvi I., *Indian journal of pharmaceutical sciences*, **68**(5): 656-657 (2006).
- Jain S.K., Agrawal G.P., Jain N.K., Indian journal of pharmaceutical sciences, 67(2): 249-251 (2005).
- Gandhimathi M, Ravi T.K. and Susan Kurian Renu, *Analytical Sciences*, **19**(12) 1675-1677 (2003).
- Mohamed Abdel Nabi El-Ries, Gehad Genidy Mohamed and Ali Kamal Attia, Yakugaku Zasshi, 128(1): 171-177 (2008).